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SUMMARY
The RID assay is one of the in vitro methods used for in-process control in the production of rabies vaccines for veterinary use.
It has been shown to be very useful for determining antigen concentration in the final bulk product. The work presented in this paper,
including the production and standardization of candidate standard reagents for use in the Radial Immunodiffusion Assay (RID) was
carried out at the Pan American Institute for Food Protection and Zoonoses (INPPAZ/PAHO/WHO). The study was completed with
the cooperation of the Faculty of Veterinary Sciences, National University of La Plata (NULP),  Argentina, where the validation of the
proposed standards and the quality control of samples from 28 different batches of rabies vaccines produced with Pasteur strain rabies
virus (PV) in BHK cells were performed. The activity of the vaccines was determined by in vivo (NIH) and in vitro (RID)assays. The
results of the candidate reagents for the reagent standardization tests showed stability, sensitivity and reproducibility. The Relative
Potency the 1.2 between the problem vaccines and the reference vaccine was estimated by variance and regression analysis. The
results of our validation study show that the INPPAZ (PAHO/WHO) is capable of producing and distributing the above-mentioned
standard reagents, as well as of providing support for the incorporation of the RID technique (sensitive, rapid and inexpensive) to the
laboratories that manufacture rabies vaccines in Latin America and the Caribbean.
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INTRODUCTION
During the past years, in vitro tests for the process control of
biological products13 such as rabies vaccines and sera have been developed
and applied world-wide for the purpose of providing manufacturers with
preliminary data on the future quality of the finished product. Such
methods include the antigen-antibody binding test1,2, the enzyme
immunoassay23 and the counterimmunoelectrophoresis technique4,5,16.
In 1975 and 1977 the radial immunodiffusion test (RID) was used
for determining inactivated antigens in vaccines against the influenza
virus (SCHILD et al.,197517; WOOD et al.,197726) and the poliovirus
(SCHILD et al., 1980)18. FERGUSON & SCHILD7, FERGUSON et
al.8,9,10 and FITZGERALD & NEEDY12 were the first to use this method
for the assay of rabies vaccines.
The RID test13,14,15 is rapid, easy to perform and sensitive; it requires
the use of reagents of proven quality and stability.The purpose of this
collaborative study between the INPPAZ (PAHO/WHO) and the Faculty
of Veterinary Sciences (NULP), Argentina was to evaluate the quality of
the standard reagents (reference vaccines and reference sera) in order to
determine the antigen concentration in cell-culture vaccines produced
in Latin America and the Caribbean.
MATERIALS AND METHODS
1. Standard Serum
1.1 Polyclonal Hyperimmune Serum
PV virus was purified with aluminum phosphate according to the
procedure described by SCHNEIDER19, inactivated with
Betapropiolactone and adsorbed in Freund’s complete adjuvant. Two
rabbits were inoculated by the intramuscular (IM) route with six doses
of PV-BHK rabies vaccine, each of 0.5 ml administered every three days.
Antibody titers were controlled by counterimmunoelectrophoresis (CIE)
and seroneutralization (SN) in mice. A booster dose of 0.8 ml of purified
PV virus was administered as follows: 0.1 ml intradermically (ID), 0.2
ml subcutaneously (SC) and 0.5 ml IM.
Blood for the tests was obtained from the marginal vein of the ear,
and antibody titers were determined by CIE and SN. The final bleeding
was performed when the rabbits showed titers higher than 1:1500 by
CIE and 1:5000 by SN.
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The serum was separated, inactivated, and distributed into ampoules
in 0.5 ml aliquots. Fifty per cent of the ampoules were stored frozen and
50%, lyophilized. Neutralizing rabies antibodies were determined in the
final batch.
1.2 PV-BHK antiglycoprotein and antiribonucleoprotein sera
The PV-BHK virus was treated with detergent and ultracen-
trifugation3,21 to separate the glycoprotein and ribonucleoprotein fractions.
These antigens were used for the booster inoculation of the rabbits
previously immunized with PV-BHK vaccine in the manner described
above for the hyperimmune polyclonal serum.
1.3 Standardization of the Polylonal Hyperimmune Serum
1% agarose in saline buffered solution (SBS) was prepared in four
immunoplates containing respectively 50 µl, 100 µl, 150 µl and 250 µl
of polyclonal hyperimmune serum. The plates were stored at 4 ºC for 10
minutes. In each, four wells 4 mm in diameter were cut in two parallel
lines. The agarose was removed and four dilutions series (1:2, 1:4, 1:8,
1:16) of the International Reference Vaccine were distributed in duplicate
in the amount of 20 µl per well. The RID technique was performed as
described in paragraph 5 below.
The linear regression parameters for the relations were determined:
log 10 of the dilutions of the International Reference Vaccine (axis x) versus
the measurements of the diameters of the precipitation zones (axis y).
2. Homologous Reference Vaccine
A batch of PV-BHK vaccine (homologous to the problem vaccines),
inactivated with Betapropiolactone without adjuvant6 was prepared and
standardized against the National Standard Vaccine by the NIH20 potency
test. The Reference Vaccine showed Activity: 1 IU/ml and average 50%
effective dose: 1:69 +/- 3 Standard Deviation (SD) Interval 1:49-1:100.
It was distributed in 0.5 ml flasks and stored at –70 ºC.
Five samples of the homologous Reference Vaccine were collected
at random. Five independent tests were performed to standardize the
vaccine.
2.1 RID Standardization of the Homologous Reference Vaccine
One percent agarose in SBS was prepared in one immunoplate with
a 250 µl volume of Polyclonal Standardized Hyperimmune Serum as
described in paragraph 1.3. The plate was stored at 4 ºC for 10 minutes
and eight parallel wells 4 mm in diameter were punched. The four series
dilutions (1:2, 1:4, 1:8, 1:16) of the Homologous Reference Vaccine
were inoculated in duplicate. The RID technique was carried out as
described in paragraph 3 below. The results were assayed following the
same procedure as in the case of the standardization of the hyperimmune
serum.
3. Problem Vaccines
Samples from twenty-eight batches of vaccines were controlled to
assess the sensitivity and specificity of the reagents. All the vaccines
were produced in BHK cells with PV rabies virus and no adjuvant. The
standard production technique was used with a 1 to 2% bovine fetal
serum in the final product. All the batches originated from laboratories
in Latin America and the Caribbean.
The activity of the vaccines was determined by the standard potency
NIH test and ranged between 0.3 and 7.3 IU/ml.
4. Radial Immunodiffusion Technique
Procedure
200 µl of each of the problem vaccines and of the Homologous
Reference Vaccine were treated with 20 µl of detergent (Emulphogene
BC 720 at 20% in SBS) and were allowed to react for 30 minutes at
room temperature.
One per cent agarose in SBS was prepared in immunoplates with
the optimum amount of the hyperimmune rabies serum: 1:250 (paragraph
1.3). Series dilutions of the problem vaccines were prepared in SBS at a
ratio of 1:2, and inoculated in duplicate at a volume of 20 µl per well.
They were allowed to diffuse for 24 hours at room temperature in a
humid chamber following which they were stored at 35 ºC for 18-24
hours in a container with SBS pH 7.2. They were then washed, dried on
Gel Bond hydrophilic paper, stained with Coomassie blue stain R-250
and left to dry at room temperature. The diameters of the precipitation
areas were measured with a millimetric ruler with a probable error of
0.5 mm.
5. Calculations
Relative potency (RP)
The relative potency is defined as the quotient between the dose of
the reference preparations (Xr) and that of the test preparations (Xp).
Both give a specific response against the reference serum in the RID
system.
To determine the RP measurements were made of the diameters of
the precipitation zone of each problem vaccine and compared with those
of the homologous Reference Vaccine (y), versus the log of the dose (x).
The relative potency is obtained from the horizontal distance between
both parallel lines as follows:
Antilog M =[ Xr – Xp – (Yr – Yp)]
                                                       b
Variance and regression analyses were carried out to determine
whether the RID tests complied with the regression, linearity, parallelism,
and homogeneity of variances11,22.
RESULTS  AND  CONCLUSIONS
Table 1 shows the linear regression parameters and correlation
coefficients obtained when immunoplates were prepared with different
concentrations of the Polyclonal Hyperimmune Serum. The sensitivity
of the plates was seen to be comparable. It was observed that all the
correlation coefficients with the different volumes of serum were close
to the unit. The 250 µl volume was selected because it produced sharper
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precipitation zones and because the correlation coefficient value was
r= -1.0. No precipitation zones were observed with 50 µl of serum and
therefore this concentration does not appear in the table.
The results of the assessment of the Homologous Reference Vaccine
were obtained on five samples of the final batch in the same number of
independent RID tests. The variance analysis was performed and the
vaccine dilutions were expressed as log 2, and the diameters of the
precipitation zones were given in millimeters. The results of the tests
did not show statistically significant differences. The diffusion diameters
of the Homologous Reference Vaccine ranged between 17 mm for the
lowest dilution and 11 mm for the highest.
It may be concluded that the dose-response relationship with both
candidate standard reagents, i.e., the Polyclonal Hyperimmune Serum
and the Homologous Reference Vaccine, was satisfactory.The results of
the RID testing of samples from 28 different batches of PV-BHK rabies
vaccines are presented in Table 2.
At the laboratories of the INPPAZ (PAHO/WHO) and of the Faculty
of Veterinary Sciences, PV-BHK rabies vaccines with a 1.2 or higher
RP complied with the Minimum 1.0 IU/ml Potency Requirement in the
in vivo NIH test, as recommended by the World Health Organization
(WHO) for vaccines for veterinary use24.
The RID test was capable of discriminating Relative Potency values
ranging between 0.6 and 1.5, equivalent to 0.6 IU/ml and 1.0 IU/ml in
the NIH test, respectively.
It may be concluded that:
a) The reference reagents produced by the INPPAZ (PAHO/WHO)
may be used as standard reagents for the implementation of the RID
technique for in-process control during the manufacture of PV-BHK
rabies vaccines for veterinary use.
b) It is essential that each laboratory producing rabies vaccines should
determine by using the RID technique, its minimum RP required to
comply with the Minimum Requirements of the in vivo Potency test
(NIH) of the final product, on the basis of the reproducibility of the
quality of its products (consistency).
RESUMO
Avaliação de reativos padrões para provas de Imunodifusão
Radial. Controle in vitro de vacinas antirrábicas
A prova de Imunodifusão Radial (IDR) é um método in vitro
conveniente para determinar a concentração de antígenos no produto
final como um todo, de vacinas anti-rábicas para uso veterinário. Os
reativos padrões candidatos para uso na prova IDR, proposta para o
controle de processo de vacinas de cultivo celular, elaboradas na América
Latina e Caribe, foram produzidos e padronizados no Instituto
Panamericano de Proteção de Alimentos e Zoonoses (INPPAZ). A
validação dos padrões e o controle de qualidade de 28 lotes de vacinas
anti-rábicas, de diferentes procedências, foram realizados na Faculdade
de Ciências Veterinárias da Universidade de La Plata, Argentina (UNLP).
Todas as vacinas foram elaboradas com virus rábico cepa Pasteur (PV)
em células BHK e sua atividade foi determinada através de provas in
vivo (NIH) e in vitro (IDR).
Os resultados dos reativos, candidatos para as provas de padronização,
demonstraram estabilidade, sensibilidade e reprodutibilidade.
Por análise de variância e de regressão foi estimada a potência relativa
de 1.2 entre as vacinas problemas e a vacina de referência.
Table 2
Results of the RID tests of samples obtained from 28 batches
of rabies vaccines
Samples RID Test NIH Test
N % (RP) ED50-A UI/ml-A
15 54 1.5 1:100 1.0
3 11 1.2 1:84 0.9
8 32 0.6 1:47 0.6
2 NC NC <1:5 NC
ED50-A: 50% Effective Dose - Average; IU/ml-A: International Units -
Average; NC: Non-calculable
Table 1
Standardization of the Polyclonal Hyperimmune serum
Serum Diameters of the precipitation zones Linear Regression
Plate Anti-PV vs
Dilution of the ReferenceVaccine
Nº  µl  1:2 1:4 1:8 1:16 (a+b.x) r*
1 100µl 16 15 13 10 18.5-6.66x -0.97
2 100µl 16 15 13 12 17.5-4.66x -0.98
3 150µl 14 13 11  8 16.5-6.66x -0.97
4 150µl 14 13 11 10 15.5-4.66x -0.98
5 250µl 14 12 10  9 15.5-5.66x -0.99
6 250µl 14 12 10 8 16-6.66x -1
 r*:correlation coefficients
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Os resultados deste estudo de validação indicam que o INPPAZ,
está em condições de elaborar e distribuir os reativos padrões acima
mencionados e apoiar a adoção da técnica de IDR (sensível, rápida,
econômica) pelos laboratórios de produção de vacinas anti-rábicas da
América Latina e Caribe.
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